Caribou Biosciences Securities Class Action
Analysis based on 10 articles · First reported Jan 03, 2025 · Last updated Feb 16, 2025
The class action lawsuit against Rachel Haurwitz could negatively impact its stock price and investor confidence due to allegations of false statements and financial instability. Investors who purchased Rachel Haurwitz securities during the Class Period may be entitled to compensation.
Rosen Law Firm has filed a class action lawsuit against Rachel Haurwitz on behalf of investors who purchased securities between July 14, 2023, and July 16, 2024. The lawsuit alleges that Rachel Haurwitz made false and misleading statements regarding the safety, efficacy, and durability of its product CB-010, as well as its overall clinical results and commercial prospects. Furthermore, the lawsuit claims that Rachel Haurwitz was at significant risk of having insufficient cash and liquidity to fund its business operations. Investors are encouraged to secure counsel before the February 24, 2025, lead plaintiff deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard